File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations

TitleDistinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations
Authors
Keywordsacute myeloid leukemia
adult
allogeneic hematopoietic stem cell transplantation
chromosome 17
chromosome 5
Issue Date2019
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105
Citation
American Journal of Hematology, 2019, v. 94 n. 6, p. 650-657 How to Cite?
AbstractThe present study aimed to define a subtype of complex/monosomal karyotype (CK/MK) acute myeloid leukemia (AML) by its distinct clinical features, p53 signaling and responses to p53 targeting agents. Ninety‐eight young adults (range: 21‐60 years; median: 49 years) with CK/MK AML were studied. They received standard induction, consolidation and allogeneic hematopoietic stem cell transplantation from siblings or matched unrelated donors if available. Chromosomal abnormalities most commonly affected chromosome 5 (30%), 7 (22%) and 17 (21%). Next generation sequencing of a 54‐myeloid gene panel were available in 76 patients. Tumor protein 53 (TP53) mutations were most common (49%) and associated with the presence of −5/5q‐ (P < .001) and −17/17p‐ (P < .001), but not −7/7q‐ (P = .370). This “typical” CK/MK AML subtype was associated with significantly lower presenting white cell counts, higher number of karyotypic abnormalities, and inferior leukemia‐free and overall survivals, compared with CK/MK AML without the typical features. Blood or bone marrow samples from typical CK/MK AML patients showed defective p53 signaling upon induction by etoposide. In vitro drug sensitivity analysis showed that they were sensitive to APR‐246 that targeted mutant p53, but resistant to MDM2 antagonist MI‐77301. Novel therapeutic strategies targeting TP53 mutations in CK/MK AML should be developed and tested in clinical trials.
Persistent Identifierhttp://hdl.handle.net/10722/275737
ISSN
2017 Impact Factor: 5.303
2015 SCImago Journal Rankings: 1.761

 

DC FieldValueLanguage
dc.contributor.authorLeung, GMK-
dc.contributor.authorZhang, C-
dc.contributor.authorNg, NKL-
dc.contributor.authorYang, N-
dc.contributor.authorLam, SSY-
dc.contributor.authorAu, CH-
dc.contributor.authorChan, TL-
dc.contributor.authorMa, ESK-
dc.contributor.authorTsui, SP-
dc.contributor.authorIp, HW-
dc.contributor.authorSo, JCC-
dc.contributor.authorNg, MHL-
dc.contributor.authorCheng, KCK-
dc.contributor.authorWong, KF-
dc.contributor.authorSiu, LLP-
dc.contributor.authorYip, SF-
dc.contributor.authorLin , SY-
dc.contributor.authorLau, JSM-
dc.contributor.authorLuk , TH-
dc.contributor.authorLee , HKK-
dc.contributor.authorLau, CK-
dc.contributor.authorKho, B-
dc.contributor.authorKwong, YL-
dc.contributor.authorLeung, AYH-
dc.date.accessioned2019-09-10T02:48:40Z-
dc.date.available2019-09-10T02:48:40Z-
dc.date.issued2019-
dc.identifier.citationAmerican Journal of Hematology, 2019, v. 94 n. 6, p. 650-657-
dc.identifier.issn0361-8609-
dc.identifier.urihttp://hdl.handle.net/10722/275737-
dc.description.abstractThe present study aimed to define a subtype of complex/monosomal karyotype (CK/MK) acute myeloid leukemia (AML) by its distinct clinical features, p53 signaling and responses to p53 targeting agents. Ninety‐eight young adults (range: 21‐60 years; median: 49 years) with CK/MK AML were studied. They received standard induction, consolidation and allogeneic hematopoietic stem cell transplantation from siblings or matched unrelated donors if available. Chromosomal abnormalities most commonly affected chromosome 5 (30%), 7 (22%) and 17 (21%). Next generation sequencing of a 54‐myeloid gene panel were available in 76 patients. Tumor protein 53 (TP53) mutations were most common (49%) and associated with the presence of −5/5q‐ (P < .001) and −17/17p‐ (P < .001), but not −7/7q‐ (P = .370). This “typical” CK/MK AML subtype was associated with significantly lower presenting white cell counts, higher number of karyotypic abnormalities, and inferior leukemia‐free and overall survivals, compared with CK/MK AML without the typical features. Blood or bone marrow samples from typical CK/MK AML patients showed defective p53 signaling upon induction by etoposide. In vitro drug sensitivity analysis showed that they were sensitive to APR‐246 that targeted mutant p53, but resistant to MDM2 antagonist MI‐77301. Novel therapeutic strategies targeting TP53 mutations in CK/MK AML should be developed and tested in clinical trials.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105-
dc.relation.ispartofAmerican Journal of Hematology-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectacute myeloid leukemia-
dc.subjectadult-
dc.subjectallogeneic hematopoietic stem cell transplantation-
dc.subjectchromosome 17-
dc.subjectchromosome 5-
dc.titleDistinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations-
dc.typeArticle-
dc.identifier.emailZhang, C: chunxiao@hku.hk-
dc.identifier.emailNg, NKL: kalamng@hku.hk-
dc.identifier.emailYang, N: yangning@hku.hk-
dc.identifier.emailKwong, YL: ylkwong@hku.hk-
dc.identifier.emailLeung, AYH: ayhleung@hku.hk-
dc.identifier.authorityKwong, YL=rp00358-
dc.identifier.authorityLeung, AYH=rp00265-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ajh.25469-
dc.identifier.pmid30900772-
dc.identifier.scopuseid_2-s2.0-85064613550-
dc.identifier.hkuros304533-
dc.identifier.volume94-
dc.identifier.issue6-
dc.identifier.spage650-
dc.identifier.epage657-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats